Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Medigus’ First Multi-center Clinical Study for MUSE™ Approved by CFDA

publication date: Feb 16, 2017
Medigus of Israel has received CFDA approval of the first multi-center clinical study for its MUSE™ system, an FDA cleared and CE marked endoscopic device to perform transoral fundoplication for the treatment of gastroesophageal reflux disease (GERD), in China. Shanghai Golden-Grand Medical Instruments, Sinopharm’s unit that is specialized in the distribution of medical devices in the gastroenterology field and Medigus' exclusive distributor of MUSETM in China, will launch the trial. More details....

Stock Symbols (NASDAQ: MDGS) (TASE: MDGS)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital